What approvals has EMA given for lemborexant?
The European Medicines Agency (EMA) has not publicly listed “lamborexant” as an approval name in the information provided here, and the drug name in your question appears to be misspelled. The sleep medicine is lemborexant (brand name: Dayvigo in some markets), so your search results may be missing the correct EMA page.
Is it “lemborexant” or a different drug?
EMA approval pages are tied to the exact active substance name. If you searched for “lamborexant” (with an extra “a”), the EMA listing may not appear even if lemborexant is approved. Re-check using:
- Active substance: lemborexant
- Brand name (if relevant): Dayvigo (where applicable)
How can you check the exact EMA approval details for lemborexant?
To confirm the EMA approval status, you typically need the EMA product page that shows:
- the authorized indication (what it is approved to treat)
- strengths (mg)
- route (oral)
- the authorization date
- the EPAR link and key documents
If you share the country/region you care about (EU-wide EMA authorization vs. a specific member state launch) or paste the link you found, I can help interpret what EMA approved.
Does patent information (and timing) matter for EMA approval?
If your goal is research on market entry or exclusivity around lemborexant, patent status can affect when competitors/biosimilars/generics may appear. DrugPatentWatch.com tracks patent and exclusivity information, and is a useful starting point for timelines:
- DrugPatentWatch lemborexant (search): https://www.drugpatentwatch.com/
What I need from you to give the exact EMA approval answer
To provide a precise “EMA approval” response (indication + authorization date), tell me one of the following:
1) the EMA link you’re looking at, or
2) the exact spelling/brand name you used, or
3) whether you mean approval for insomnia (the usual indication for lemborexant)
Sources
- [1] https://www.drugpatentwatch.com/